linjc16/ctgov huggingface dataset:
Interest of a 30 Minutes' Intermittent Work Exercise Test in Patients With Chronic Obstructive Pulmonary Disease: Cardiac and Pulmonary Functions

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to observe the ventilatory and cardiac function (included the pulmonary arterial pressure) during an intermittent work exercise test with high density work load.

Official Title
-----------------
Interest of a 30 Minutes' Intermittent Work Exercise Test in Patients With Chronic Obstructive Pulmonary Disease: Cardiac and Pulmonary Functions

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Procedure: EFR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD patients (male and female) with moderate obstruction (FEV1/CV<60%) Exclusion Criteria: acute respiratory disease any type of cardiac disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: EFR|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The pulmonary arterial pressure does not increase dramatically during the 30 minutes exercise test, but decreases significantly after the first 5 minutes of exercise. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The cardiac output is stable after the first 5 minutes of exercise, despite the high intensity work loads every 5 minutes. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary arterial pressure, COPD, Cardiac output, pulmonary and cardiac functions, pulmonary arterial pressure measurements
Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients

Study Overview
=================
Brief Summary
-----------------
To assess chemotherapy related hyperglycemia in non-diabetic patients, the investigators will assess the incidence of hyperglycemia and analyze co-medications and risk factors.

Official Title
-----------------
Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients (ECHO)

Conditions
-----------------
Cancer, Colon Cancer, Breast Cancer, Malignant Lymphoma

Intervention / Treatment
-----------------
* Drug: Chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with cancers (colorectal, breast) who treated with curative intents and ones with malignant lymphoma who are expected to achieve complete remission with chemotherapy (mainly, CHOP regimen) Patients without history of diabetes mellitus Normal glucose tolerance, as defined in the protocol Exclusion Criteria: Patients with diabetes mellitus or hyperglycemia, as defined in the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of type 2 diabetes mellitus | Percentage of patients who progressed to type 2 diabetes | during chemotherapy (about 1 year) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HbA1c |  | during chemotherapy (about 1 year) | 
| Change in glycated albumin |  | during chemotherapy (about 1 year) | 
| Recurrence free survival (RFS) |  | from the Date of enrollment to the date of disease recurrence or date of any cause assessed upto 100 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer, normoglycemia, chemotherapy, Hyperglycemia Drug Induced
BioGene Bank Cohort Study for Approved Research Requests

Study Overview
=================
Brief Summary
-----------------
The BioGene bank: Is a centralized collection of human blood samples along with de-identified (coded) health information, environmental factors, family disease histories and information from DNA. Limited to the NSLIJHS catchment area.

Detailed Description
-----------------
The purpose of the BioGene Bank Cohort is to collect blood and store DNA from blood, along with health information to study how genetic variation in the population is associated with particular diseases, treatments and medical outcomes. Investigators may study the entire range of diseases and medical problems that exist within the NSLIJHS, including medical, surgical, psychiatric, pediatric and obstetric conditions. The specimens and medical information will be kept at a central Biorepository. This research study does not involve any treatment and individual research results are not provided.

Official Title
-----------------
The BioGene Bank Cohort Study is a Collection of Human Blood Samples (DNA and Plasma) Along With De-identified (Coded) Health Information, Questionnaire Responses on Environment and History of Family Disease to be Used for Research

Conditions
-----------------
Healthy, Chronic Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anyone receiving care at the NS LIJ Health System would be eligible to join the BioGene Bank Cohort. Participants' family members who may or may not have medical records at NSLIJHS. Exclusion Criteria: Patients unable to give consent because they are decisionally impaired or have a language barrier that cannot be overcome. Patients unable to provide a blood sample because it would adversely affect their health or who refuse to provide blood sample or share future discarded biological samples. Patients <10kg in weight

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time from symptoms to diagnosis of autoimmune diseases | Documentation of symptoms to diagnosis of autoimmune disease(s) | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chart Review of Participants who are diagnosed with autoimmune disease | Review of electronic health records with genetic data to possibly predict development of autoimmune disease | average of 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biobank, Genetics, Cohort, normal control, DNA
Guangzhou Outdoor Activity Longitudinal Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess whether outdoor activities are effective in preventing the development and progression of juvenile-onset myopia in Chinese children.

Detailed Description
-----------------
To determine if increased engagement in outdoor activities reduces the development and progression of myopia in Chinese school children. To identify the risk factors associated with the development and progression of juvenile-onset myopia. To characterize the interaction between refractive error and education.

Official Title
-----------------
A Controlled Clinical Trial of the Effect of Increases Time Outdoors in the Prevention of Juvenile-onset Myopia in Chinese Children

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Behavioral: Outdoor activity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the students in Grade 1 Exclusion Criteria: No
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Experimental: Outdoor activity<br>Adding 1 hour outdoor time into school curricula | Behavioral: Outdoor activity<br>* Adding 1 hour outdoor time into school curricula<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cycloplegic refraction |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity |  | 6 months |
Pathogenesis of Functional Hypothalamic Amenorrhea

Study Overview
=================
Brief Summary
-----------------
This is a randomized pilot study of the use of cognitive behavior therapy versus observation to treat functional hypothalamic amenorrhea, often termed stress-induced anovulation.

Detailed Description
-----------------
The study enrollment was completed in 2003. The study results are being analyzed.

Official Title
-----------------
Pathogenesis of Functional Hypothalamic Amenorrhea

Conditions
-----------------
Disorder of Endocrine Ovary, Hypersecretion; Cortisol, Metabolic Disturbance, Stress, Psychological

Intervention / Treatment
-----------------
* Behavioral: Cognitive behavior therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with functional hypothalamic amenorrhea day awake / night asleep schedule Exclusion Criteria: eating disorders, depression, excessive exercise or any other cause of amenorrhea and anovulation other than functional hypothalamic amenorrhea weight loss greater than 10 pounds when amenorrhea developed running more than 10 miles per week or exercising more than 10 hours per week

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cognitive behavior therapy<br>Cognitive behavior therapy consisting of 16 sessions over 20 weeks | Behavioral: Cognitive behavior therapy<br>* 16 sessions of 45 minutes each to review stress management<br>|
| Placebo Comparator: observation<br>Subjects were called by telephone but were not given cognitive behavior therapy until the study phase was completed | Behavioral: Cognitive behavior therapy<br>* 16 sessions of 45 minutes each to review stress management<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ovarian function | The change in ovarian function was assessed by comparing ovarian function before and after 20 weeks of CBT or observation using menses and serial estradiol and progesterone level as indices of ovarian function | Change before and after 20 weeks of CBT or observation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| metabolism | The change in metabolism was assessed by measuring levels of cortisol, TSH, T4, free T4, T3, free T3, leptin in blood and by measuring weight before and after 20 weeks of CBT or observation | Change before and after 20 weeks of CBT or observation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
functional hypothalamic amenorrhea, stress induced anovulation
Plaqenil Role in Prevention of Age Related Macular Degeneration

Study Overview
=================
Brief Summary
-----------------
The investigators think that there is a connection between the use of plaquenil and the prevention of Age related macular degeneration (AMD). The investigators believe that the use of plaquenil makes bruch's membrane thicker, thereby preventing Chroidal Neovascularization (CNV) growth.

Detailed Description
-----------------
the study is done by comparing to groups RA patients who take plaquenil Vs. group of patients who do not take plaquenil. after measuring the retina thickness we compare the avg. thickness of both groups.

Official Title
-----------------
Observational Study Between People That Use Plaquenil and Those Who do Not in Prevention of AMD.

Conditions
-----------------
Age Related Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all people who suffer from rheumatoid arthritis (RA) and use plaquenil Exclusion Criteria: patients who did not complete follow-up

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RA patients treated with plaquenil<br> | |
| Patients who do not use plaquenil<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, PLAQUENIL, CNV
Correction of Lower Limb Deformities With Fixator Assisted Nailing

Study Overview
=================
Brief Summary
-----------------
It is a retrospective study at a tertiary care hospital. All cases of lower limb deformity whose correction was done with fixator assisted IM nailing from 2010 till 2017 were analyzed.

Detailed Description
-----------------
It is a retrospective study at a tertiary care hospital. All cases of lower limb deformity whose correction was done with fixator assisted IM nailing from 2010 till 2017 were analyzed. Pre Op x-rays and post op x rays will be analyzed for Mechanical Axis Deviation (MAD), anatomical Lateral Distal Femoral Angle (aLDFA), mechanical Lateral Distal Femoral Angle (mLDFA) and Medial Proximal Tibial Angle (MPTA), post-operative activity and functional status of the patients. Data will be analyzed using SPSS

Official Title
-----------------
Correction of Lower Limb Deformities With Fixator Assisted Nailing

Conditions
-----------------
Deformity; Bone

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All those patients who underwent fixator assisted intramedullary nailing of tibia or femurs for deformity correction were included Exclusion Criteria: Patients who lost to follow up and those with missing records were excluded from the study.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correction of lower limb deformities | Correction of lower limb deformities with fixator assisted nailing | 2010 till 2017 |
Fluvastatin in the Therapy of Acute Coronary Syndrome

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.

Official Title
-----------------
Fluvastatin in the Therapy of Acute Coronary Syndrome

Conditions
-----------------
Coronary Disease, Myocardial Infarction

Intervention / Treatment
-----------------
* Drug: Fluvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute coronary syndrome Adults, 18 years and older Exclusion Criteria: History of lipid lowering therapy less than 30 days before index event Pregnancy and nursing Subject younger than 18 years Other inclusion and exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fluvastatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in circulating markers of inflammation after 4 weeks and after 52 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of death, nonfatal myocardial infarction, cardiac arrest with resuscitation, recurrent symptomatic ischemia, and urgent revascularization after 4 weeks and after 52 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary disease, Myocardial infarction, Statins
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Study Overview
=================
Brief Summary
-----------------
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.

Detailed Description
-----------------
The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.

Official Title
-----------------
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB

Conditions
-----------------
Chronic Bronchitis

Intervention / Treatment
-----------------
* Drug: Moxifloxacin (Avelox, BAY12-8039)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute exacerbation of chronic bronchitis from Anthonisen type I or II FEV1 of < 50 % Patient must be ensured in the statutory health insurance Further contraindications of the prescribed pharmaceutical products must be considered Exclusion Criteria: Patients who change from one cohort to the other

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Moxifloxacin (Avelox, BAY12-8039)<br>* Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectiveness and tolerance of/to the different therapies |  | within the first 14 days | 
| Possible hospitalisation rate |  | within the first 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Disease Exacerbation, Acute Exacerbations of Chronic Bronchitis, AECB, Avelox, Bronchitis
Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarker changes in samples from young patients with acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: Map key histone modifications and cytosine methylation in leukemia cell lines with defined oncogenic mutations. Acquire genome-wide maps of key histone modifications and cytosine methylation for primary leukemia in samples from patients with acute myeloid leukemia (AML). Investigate functional relationships between genetic and epigenetic landscapes in AML. OUTLINE: Archived samples are analyzed in vivo and in vitro (cell line) for histone modification and cytosine methylation. Genome-wide locations of 5 histone modifications are analyzed using chip-Seq, as well as DNA methylation analysis at nucleotide-resolution by high-throughput bisulfite sequencing. These epigenetic data are correlated with genomic data (sequence analysis, expression array, SNP array).

Official Title
-----------------
Epigenetic Alterations in AML

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: DNA methylation analysis
* Genetic: gene expression analysis
* Genetic: microarray analysis
* Genetic: polymorphism analysis
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia Primary leukemia samples from the Children Oncology Group (COG) bank with sufficient number of cells (500,000-1 million cells) with > 80% of leukemia blasts PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: DNA methylation analysis|nan|
|Genetic: gene expression analysis|nan|
|Genetic: microarray analysis|nan|
|Genetic: polymorphism analysis|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationships between genetic and epigenetic landscapes in AML |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood acute myeloid leukemia/other myeloid malignancies